Defective ANF-R2/ANP-C receptor-mediated signalling in hypertension.
In the present studies we have shown that atrial natriuretic factor (peptide) receptor of ANF-R2/ANP-C type is coupled to adenylyl cyclase/cAMP signal transduction system through Gi-regulatory protein and is implicated in mediating some of the physiological responses of atrial natriuretic factor or peptide (ANP). ANF-R2/ANP-C receptor-mediated adenylyl cyclase inhibition was altered in hypertension. This alteration was tissue specific. In heart, aorta, brain and adrenal, the extent of inhibition of adenylyl cyclase by ANP was enhanced in SHR as compared to age-matched WKY, whereas in platelets, the ANP-mediated inhibition was completely attenuated. The enhanced inhibition of adenylyl cyclase by ANP was also observed in heart and aorta from DOCA-salt hypertensive rats. In addition, the augmented inhibition of adenylyl cyclase by ANP was observed in 2 weeks and older SHR but not in 3-5 days old SHR. Similarly, in DOCA-salt hypertensive rats, the enhanced inhibition of adenylyl cyclase by ANP was observed after 2 weeks of DOCA-salt treatment when the blood pressure was also enhanced, however one week older SHR but not in 3-5 days old SHR. Similarly, in DOCA-salt hypertensive rats, the enhanced inhibition of adenylyl cyclase by ANP was observed after 2 weeks of DOCA-salt treatment when the blood pressure and augmented ANP-mediated inhibition of adenylyl of DOCA-salt treatment did not result in an augmented blood pressure and augmented ANP-mediated inhibition of adenylyl cyclase, suggesting that blood pressure increase may be responsible for the enhanced responsiveness of ANP to adenylyl cyclase inhibition. However, in genetic model of hypertension, the increased inhibition of adenylyl cyclase by ANP at 2 weeks of age (when the blood pressure is normal) may be implicated in the pathogenesis of hypertension. The augmented inhibition of adenylyl cyclase in cardiovascular tissues from SHR and DOCA-salt hypertensive rats may be due to the upregulation of ANF-R2/ANP-C receptors or due to the amplification of post-receptor signalling mechanisms.
Marcil
J
J
Department of Physiology, Faculty of Medicine, University of Montreal, Canada.
Anand-Srivastava
M B
MB
D000262:Adenylyl Cyclases / Q000502:physiology; D000367:Age Factors; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000502:physiology*; D000242:Cyclic AMP / Q000502:physiology; D003900:Desoxycorticosterone; D019204:GTP-Binding Proteins / Q000502:physiology; D006162:Guanylate Cyclase / Q000502:physiology; D006973:Hypertension / Q000503:physiopathology*; D051381:Rats; D011918:Rats, Inbred SHR / Q000502:physiology; D017461:Receptors, Atrial Natriuretic Factor / Q000502:physiology*; D015398:Signal Transduction
D003900:Desoxycorticosterone; D009320:Atrial Natriuretic Factor; D000242:Cyclic AMP; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases; D006162:Guanylate Cyclase; D017461:Receptors, Atrial Natriuretic Factor